ImmunityBio, Inc. (IBRX)
| Market Cap | 8.91B +275.5% |
| Revenue (ttm) | 140.98M +351.5% |
| Net Income | -854.53M |
| EPS | -0.89 |
| Shares Out | 1.05B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,203,766 |
| Open | 7.88 |
| Previous Close | 7.76 |
| Day's Range | 7.58 - 8.56 |
| 52-Week Range | 1.91 - 12.43 |
| Beta | 0.07 |
| Analysts | Strong Buy |
| Price Target | 12.57 (+47.71%) |
| Earnings Date | May 7, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $12.57, which is an increase of 47.71% from the latest price.
News
ImmunityBio price target lowered to $12 from $13 at BTIG
BTIG lowered the firm’s price target on ImmunityBio (IBRX) to $12 from $13 and keeps a Buy rating on the shares after its Q1 results, reaffirming the $44.2M in ANKTIVA
ImmunityBio reports Q1 EPS (62c) vs (15c) last year
Reports Q1 revenue $44.2M, consensus $43.94M. “We continue to see strong demand for ANKTIVA from both new prescribers and physicians expanding use across multiple eligible patients, including in the m...
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company...
ImmunityBio presents new comparison results on Anktiva, TAR-200
ImmunityBio (IBRX) announced it will present new treatment comparison results evaluating Anktiva plus Bacillus Calmette-Guerin versus nadofaragene firadenovec-vncg and TAR-200 in patients with non-mus...
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA® (...
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt
Important Notice Regarding Alleged ANKTIVA Drug Efficacy Misrepresentations NEW YORK, April 30, 2026 /PRNewswire/ -- SueWallSt notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class actio...
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (“ImmunityBio” or the “Company”) for potential ...
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt
Alert: Claims Focus on Alleged Misbranding and Unapproved Route of Administration for ANKTIVA NEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) ...
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP: Do you, or did you, own shares of ImmunityBio, Inc. (NASDAQ: IBRX)? Did you purchase your shares between January 19, 2026 and March 24, 2026, inclusive?
ImmunityBio announces availability of ANKTIVA in Saudi Arabia
ImmunityBio (IBRX) announced that ANKTIVA is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in...
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially avail...
IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: I...
ImmunityBio call volume above normal and directionally bullish
Bullish option flow detected in ImmunityBio (IBRX) with 29,532 calls trading, 1.2x expected, and implied vol increasing over 4 points to 105.42%. May-26 7.5 calls and 4/24 weekly 8.5 calls
IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against ImmunityBio, Inc....
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investors of the May 26, 2026 deadline to seek the role of lea...
ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - April 15, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio...
ImmunityBio reports preliminary Q1 net product revenue $44.2M
Consensus $43.17M. ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries. Additionally, the pivotal BCG-naive CIS trial is fully enrolled,...
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending M...
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at i...
ImmunityBio addresses FDA correspondence, reaffirms commitment to ad compliance
ImmunityBio (IBRX) announced it has submitted a comprehensive response to the U.S. Food and Drug Administration, FDA,Office of Prescription Drug Promotion, OPDP, regarding issues raised on March 13, 2...
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Ad...
ImmunityBio announces $100M of financing transactions
ImmunityBio (IBRX) has secured $75M in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, increasing the total committed capital under the Agreement t...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 million in non-dilutive fina...
ImmunityBio announces IDMC says QUILT-2.005 adequately powered
ImmunityBio (IBRX) announced that based on the Independent Data Monitoring Committee, IDMC, review of the interim data, the committee recommended that the study is adequately powered to detect the pre...
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring C...